Filing Flows › Avita Medical (RCEL) › Guidance & outlook
Avita Medical (RCEL) guidance and outlook
Avita Medical (RCEL) raised its guidance on Nov 5, 2026: Revenue $92.0M–$94.0M for FY2026; Revenue $71.6M for FY2025; Gross margin 88.4% for FY2026. Avita Medical's 10-Q filed Nov 5, 2026 makes 13 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $92.0M–$94.0M | raised |
| Revenue | FY2025 | $71.6M | new |
| Revenue | Q4 2026 | $24.9M–$26.9M | new |
| Gross margin | FY2026 | 88.4% | new |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- By prioritizing burn and trauma centers, we are targeting the most critical segments of acute wound care to maximize clinical impact and drive adoption across our portfolio.
- Pursuing additional business development opportunities complementary to our target wound care markets.
- These changes could reduce demand for our products, particularly if healthcare providers face lower margins or additional administrative burdens.
- Under the agreement, we will maintain a supply of RECELL for deployment in mass casualty incidents and provide associated readiness and support services.
- We believe gross margin for RECELL products on a standalone basis will be in the range of 85% to 90% for future quarters.
- Our Consolidated Financial Statements have been prepared on the basis that we will continue as a going concern for the next 12 months.
- Based on our liquidity position and current forecast of operating results and cash flows, management has now concluded that substantial doubt about our ability to continue as a going concern no longer exists, and that we have sufficient liquidity to meet our obligations as they become due within the next twelve months following the date of issuance of these Consolidated Financial Statements.
- We aim to manage capital so that we can continue as a going concern while also maintaining optimal returns to stockholders, as well as other benefits for our stakeholders.
- We also aim to maintain a capital structure that ensures the lowest cost of capital available to us.
- We will sell PermeaDerm for such sales to Stedical at a ten percent premium to our actual manufacturing costs.
- For PermeaDerm manufactured for Stedical to sell outside of the U.S., primarily in Asia, we will sell such PermeaDerm to Stedical at a fixed price per carton plus a 10% manufacturing fee, subject to a reasonable volume cap.
- While we have no committed plans to issue further shares on the market, we will continue to assess market conditions.
Avita Medical's latest quarter
Avita Medical, Q3 2026: revenue $26.1M (+53% year over year), operating margin -10.1%, net loss $6.2M, operating cash flow −$710K. The chart follows the revenue to costs, profit and cash.
Questions
Did Avita Medical raise or lower its guidance?
Avita Medical (RCEL) raised its guidance on Nov 5, 2026: Revenue $92.0M–$94.0M for FY2026; Revenue $71.6M for FY2025; Gross margin 88.4% for FY2026.
What does Avita Medical expect?
By prioritizing burn and trauma centers, we are targeting the most critical segments of acute wound care to maximize clinical impact and drive adoption across our portfolio. Pursuing additional business development opportunities complementary to our target wound care markets. These changes could reduce demand for our products, particularly if healthcare providers face lower margins or additional administrative burdens.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.